Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 6, 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.
Read more at globenewswire.com
